Show simple item record

dc.contributor.authorLau, Suzanne K
dc.contributor.authorBoutros, Paul C
dc.contributor.authorPintilie, Melania
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorZhu, Chang-Qi
dc.contributor.authorStrumpf, Dan
dc.contributor.authorJohnston, Michael R
dc.contributor.authorDarling, Gail
dc.contributor.authorKeshavjee, Shaf
dc.contributor.authorWaddell, Thomas K
dc.contributor.authorLiu, Ni
dc.contributor.authorLau, Davina
dc.contributor.authorPenn, Linda Z
dc.contributor.authorShepherd, Frances A
dc.contributor.authorJurisica, Igor
dc.contributor.authorDer, Sandy D
dc.contributor.authorTsao, Ming-Sound
dc.date.accessioned2009-06-12T10:32:21Z
dc.date.available2009-06-12T10:32:21Z
dc.date.issued2007-12-10
dc.identifier.citationThree-gene prognostic classifier for early-stage non small-cell lung cancer. 2007, 25 (35):5562-9 J. Clin. Oncol.en
dc.identifier.issn1527-7755
dc.identifier.pmid18065728
dc.identifier.doi10.1200/JCO.2007.12.0352
dc.identifier.urihttp://hdl.handle.net/10541/70265
dc.description.abstractPURPOSE: Several microarray studies have reported gene expression signatures that classify non-small-cell lung carcinoma (NSCLC) patients into different prognostic groups. However, the prognostic gene lists reported to date overlap poorly across studies, and few have been validated independently using more quantitative assay methods. PATIENTS AND METHODS: The expression of 158 putative prognostic genes identified in previous microarray studies was analyzed by reverse transcription quantitative polymerase chain reaction in the tumors of 147 NSCLC patients. Concordance indices and risk scores were used to identify a stage-independent set of genes that could classify patients with significantly different prognoses. RESULTS: We have identified a three-gene classifier (STX1A, HIF1A, and CCR7) for overall survival (hazard ratio = 3.8; 95% CI, 1.7 to 8.2; P < .001). The classifier was also able to stratify stage I and II patients and further improved the predictive ability of clinical factors such as histology and tumor stage. The predictive value of this three-gene classifier was validated in two large independent microarray data sets from Harvard and Duke Universities. CONCLUSION: We have identified a new three-gene classifier that is independent of and improves on stage to stratify early-stage NSCLC patients with significantly different prognoses. This classifier may be tested further for its potential value to improve the selection of resected NSCLC patients in adjuvant therapy.
dc.language.isoenen
dc.subjectLung Canceren
dc.subjectCancer Stagingen
dc.subjectTumour Markersen
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.meshGene Expression Regulation, Neoplastic
dc.subject.meshGenetic Screening
dc.subject.meshHumans
dc.subject.meshHypoxia-Inducible Factor 1, alpha Subunit
dc.subject.meshLung Neoplasms
dc.subject.meshNeoplasm Staging
dc.subject.meshPrognosis
dc.subject.meshReceptors, CCR7
dc.subject.meshReverse Transcriptase Polymerase Chain Reaction
dc.subject.meshSyntaxin 1
dc.subject.meshTumor Markers, Biological
dc.titleThree-gene prognostic classifier for early-stage non-small-cell lung canceren
dc.typeArticleen
dc.contributor.departmentPrincess Margaret Hospital, 610 University Ave, Toronto, Ontario, Canada.en
dc.identifier.journalJournal of Clinical Oncologyen
html.description.abstractPURPOSE: Several microarray studies have reported gene expression signatures that classify non-small-cell lung carcinoma (NSCLC) patients into different prognostic groups. However, the prognostic gene lists reported to date overlap poorly across studies, and few have been validated independently using more quantitative assay methods. PATIENTS AND METHODS: The expression of 158 putative prognostic genes identified in previous microarray studies was analyzed by reverse transcription quantitative polymerase chain reaction in the tumors of 147 NSCLC patients. Concordance indices and risk scores were used to identify a stage-independent set of genes that could classify patients with significantly different prognoses. RESULTS: We have identified a three-gene classifier (STX1A, HIF1A, and CCR7) for overall survival (hazard ratio = 3.8; 95% CI, 1.7 to 8.2; P < .001). The classifier was also able to stratify stage I and II patients and further improved the predictive ability of clinical factors such as histology and tumor stage. The predictive value of this three-gene classifier was validated in two large independent microarray data sets from Harvard and Duke Universities. CONCLUSION: We have identified a new three-gene classifier that is independent of and improves on stage to stratify early-stage NSCLC patients with significantly different prognoses. This classifier may be tested further for its potential value to improve the selection of resected NSCLC patients in adjuvant therapy.


This item appears in the following Collection(s)

Show simple item record